tetano
Editor, Senior Moderator
Front Immunol
. 2023 Mar 15;14:1142394.
doi: 10.3389/fimmu.2023.1142394. eCollection 2023.
Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice
Xingxing Li[SUP] 1 [/SUP], Jingjing Liu[SUP] 1 2 [/SUP], Wenjuan Li[SUP] 1 [/SUP], Qinhua Peng[SUP] 1 [/SUP], Miao Li[SUP] 1 [/SUP], Zhifang Ying[SUP] 3 [/SUP], Zelun Zhang[SUP] 1 [/SUP], Xinyu Liu[SUP] 1 [/SUP], Xiaohong Wu[SUP] 1 [/SUP], Danhua Zhao[SUP] 1 [/SUP], Lihong Yang[SUP] 1 [/SUP], Shouchun Cao[SUP] 1 [/SUP], Yanqiu Huang[SUP] 1 [/SUP], Leitai Shi[SUP] 1 [/SUP], Hongshan Xu[SUP] 1 [/SUP], Yunpeng Wang[SUP] 1 [/SUP], Guangzhi Yue[SUP] 1 [/SUP], Yue Suo[SUP] 1 [/SUP], Jianhui Nie[SUP] 4 [/SUP], Weijin Huang[SUP] 4 [/SUP], Jia Li[SUP] 1 [/SUP], Yuhua Li[SUP] 1 [/SUP]
Affiliations
Abstract
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) variants has been associated with the transmission and pathogenicity of COVID-19. Therefore, exploring the optimal immunisation strategy to improve the broad-spectrum cross-protection ability of COVID-19 vaccines is of great significance. Herein, we assessed different heterologous prime-boost strategies with chimpanzee adenovirus vector-based COVID-19 vaccines plus Wuhan-Hu-1 (WH-1) strain (AdW) and Beta variant (AdB) and mRNA-based COVID-19 vaccines plus WH-1 strain (ARW) and Omicron (B.1.1.529) variant (ARO) in 6-week-old female BALB/c mice. AdW and AdB were administered intramuscularly or intranasally, while ARW and ARO were administered intramuscularly. Intranasal or intramuscular vaccination with AdB followed by ARO booster exhibited the highest levels of cross-reactive IgG, pseudovirus-neutralising antibody (PNAb) responses, and angiotensin-converting enzyme-2 (ACE2)-binding inhibition rates against different 2019-nCoV variants among all vaccination groups. Moreover, intranasal AdB vaccination followed by ARO induced higher levels of IgA and neutralising antibody responses against live 2019-nCoV than intramuscular AdB vaccination followed by ARO. A single dose of AdB administered intranasally or intramuscularly induced broader cross-NAb responses than AdW. Th1-biased cellular immune response was induced in all vaccination groups. Intramuscular vaccination-only groups exhibited higher levels of Th1 cytokines than intranasal vaccination-only and intranasal vaccination-containing groups. However, no obvious differences were found in the levels of Th2 cytokines between the control and all vaccination groups. Our findings provide a basis for exploring vaccination strategies against different 2019-nCoV variants to achieve high broad-spectrum immune efficacy.
Keywords: ARCoV; COVID-19; ChAdTS-S; SARS-COV-2 variants; heterologous prime-boost; intramuscular; intranasal.
. 2023 Mar 15;14:1142394.
doi: 10.3389/fimmu.2023.1142394. eCollection 2023.
Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice
Xingxing Li[SUP] 1 [/SUP], Jingjing Liu[SUP] 1 2 [/SUP], Wenjuan Li[SUP] 1 [/SUP], Qinhua Peng[SUP] 1 [/SUP], Miao Li[SUP] 1 [/SUP], Zhifang Ying[SUP] 3 [/SUP], Zelun Zhang[SUP] 1 [/SUP], Xinyu Liu[SUP] 1 [/SUP], Xiaohong Wu[SUP] 1 [/SUP], Danhua Zhao[SUP] 1 [/SUP], Lihong Yang[SUP] 1 [/SUP], Shouchun Cao[SUP] 1 [/SUP], Yanqiu Huang[SUP] 1 [/SUP], Leitai Shi[SUP] 1 [/SUP], Hongshan Xu[SUP] 1 [/SUP], Yunpeng Wang[SUP] 1 [/SUP], Guangzhi Yue[SUP] 1 [/SUP], Yue Suo[SUP] 1 [/SUP], Jianhui Nie[SUP] 4 [/SUP], Weijin Huang[SUP] 4 [/SUP], Jia Li[SUP] 1 [/SUP], Yuhua Li[SUP] 1 [/SUP]
Affiliations
- PMID: 37006275
- PMCID: PMC10050358
- DOI: 10.3389/fimmu.2023.1142394
Abstract
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) variants has been associated with the transmission and pathogenicity of COVID-19. Therefore, exploring the optimal immunisation strategy to improve the broad-spectrum cross-protection ability of COVID-19 vaccines is of great significance. Herein, we assessed different heterologous prime-boost strategies with chimpanzee adenovirus vector-based COVID-19 vaccines plus Wuhan-Hu-1 (WH-1) strain (AdW) and Beta variant (AdB) and mRNA-based COVID-19 vaccines plus WH-1 strain (ARW) and Omicron (B.1.1.529) variant (ARO) in 6-week-old female BALB/c mice. AdW and AdB were administered intramuscularly or intranasally, while ARW and ARO were administered intramuscularly. Intranasal or intramuscular vaccination with AdB followed by ARO booster exhibited the highest levels of cross-reactive IgG, pseudovirus-neutralising antibody (PNAb) responses, and angiotensin-converting enzyme-2 (ACE2)-binding inhibition rates against different 2019-nCoV variants among all vaccination groups. Moreover, intranasal AdB vaccination followed by ARO induced higher levels of IgA and neutralising antibody responses against live 2019-nCoV than intramuscular AdB vaccination followed by ARO. A single dose of AdB administered intranasally or intramuscularly induced broader cross-NAb responses than AdW. Th1-biased cellular immune response was induced in all vaccination groups. Intramuscular vaccination-only groups exhibited higher levels of Th1 cytokines than intranasal vaccination-only and intranasal vaccination-containing groups. However, no obvious differences were found in the levels of Th2 cytokines between the control and all vaccination groups. Our findings provide a basis for exploring vaccination strategies against different 2019-nCoV variants to achieve high broad-spectrum immune efficacy.
Keywords: ARCoV; COVID-19; ChAdTS-S; SARS-COV-2 variants; heterologous prime-boost; intramuscular; intranasal.